or in the PMNs that have an effect on phagocytic activity but ANCA may play a role by decreasing phagocytic ability.
Introduction
Anti-neutrophil cytoplasmic antibody (ANCA)-associated small vessel vasculitis (AAV) is a group of autoimmune diseases affecting small blood vessels of mainly kidneys and the respiratory tract [1] . These diseases include granulomatosis with polyangiitis (GPA) (formerly known as Wegener's granulomatosis [2] ), microscopic polyangiitis (MPA) and Churg-Strauss syndrome (CSS).
The antigens towards which the ANCAs are directed were discovered in the late 1980s and are either myeloperoxidase (MPO) [3] , usually associated with MPA, or proteinase 3 (PR3) [4, 5] , usually associated with GPA. Both antigens are granule proteins abundant in neutrophils. PR3 shows a bimodal surface expression pattern on resting neutrophils [6] . The surface expression of both autoantigens is increased following degranulation [7] . Apoptosis also increases PR3, but not MPO, surface expression, and this seems to be independent of degranulation [8] . This study also proposes PR3 as a 'don't eat me' signal associated with phosphatidylserine exposure during apoptosis. PR3 membrane expression and association with different molecular partners is, however, not fully elucidated [9] .
There is extensive evidence for a pathogenic role of ANCA in AAV. ANCAs are able to activate cytokine-primed neutrophils, by binding to its antigen on the neutrophil surface, to release their granules and produce reactive oxygen species (ROS) [10] , and are capable of transferring the disease [11] . An animal model for GPA has been missing up to recently when a mouse model with humanized mice developed disease after passive transfer of anti-PR3 ANCA [12] . It is as yet unknown how these autoantibodies arise, although there are many theories. One such theory suggests a connection with infections, and in fact 63 % of GPA patients have chronic Staphylococcus aureus nasal carriage, supporting this theory [13] . Furthermore, autoantibodies directed against lysosomal-associated membrane protein 2 (LAMP-2) were discovered recently in active AAV. These cross-react with FimH, a protein common in Gram-negative bacteria, suggesting an infection with Gram-negative bacteria as an initiating factor in the development of AAV [14] , although this is still the subject of debate [15, 16] .
Another proposed mechanism is that dysregulation of apoptotic cell clearance contributes to autoimmunity. Apoptotic cell clearance is normally a non-inflammatory process, but if the system is overwhelmed apoptotic cells can progress into secondary necrosis, an inflammatory process. This might trigger maturation signals in dendritic cells (DCs) which may, in turn, stimulate an immune response towards autoantigens [17] . According to the danger theory first proposed by Matzinger, the immune system would recognize the tissue damage as a danger signal and start to react [18] . Dysregulated clearance of apoptotic cells has also been proposed for other autoimmune diseases, such as systemic lupus erythematosus (SLE) [19] .
Neutrophils have been shown to be key players in AAV; in a MPO-ANCA mouse model, neutrophil depletion abrogated the development of necrotizing and crescentic glomerular nephritis (NCGN) [20] and activated neutrophils have been found in renal biopsies of AAV, mediating damage to the vascular wall [21] . Recent data from our group has also shown that polymorphonuclear neutrophils (PMNs) from AAV patients survive longer in vitro compared to healthy blood donors (HBDs) [22] . This might contribute to the accumulation of dying neutrophils seen commonly around vessels in AAV patients [23] .
Other causes of this accumulation could be an intrinsic defect in the cells involved in apoptotic cell clearance; for example, in the monocytes/MØs or in the neutrophils. It has been shown previously that the CD14 + CD16 + subpopulation of monocytes is increased in several chronic inflammatory diseases, such as rheumatoid arthritis [24] . We have also shown previously that monocytes from patients express more PR3 compared to
HBDs [25] . Specific differences in gene expression have also been found for several genes in a gene array study comparing leucocytes from AAV, SLE patients and HBDs.
The results from these studies indicate that neutrophils are particularly involved in AAV pathogenesis [26] . This suggests that the monocyte/MØ -and/or neutrophil populations in AAV patients deviate to some extent from HBDs.
In this study we hypothesize that there is an intrinsic dysfunctional phagocytosis in AAV patients, either in the ability of MØs to clear apoptotic cells or in the ability of apoptotic neutrophils to become cleared.
Material and methods

Blood samples and patients
Blood from patients and HBDs was drawn in ethylenediamine tetraacetic acid (EDTA) tubes if not stated otherwise. The blood was used within 2 h. Written informed consent was taken from all donors and these studies were conducted with permission from the Ethical Committee, Lund University, Sweden. AAV patients were, in most cases, in remission as assessed by Birmingham Vasculitis Activity Score (BVAS). They all had a diagnosis of MPA or GPA. Patient data are summarized in table 1.
Differential blood cell counts
Six ml blood was taken from AAV patients, patients with a renal transplant (TP) and
HBDs and sent to the Clinical Chemistry laboratory at Skåne University Hospital for differential blood cell counts. Monocytes, neutrophils, lymphocytes, eosinophils and basophils were reported in absolute numbers.
Monocyte and plasmacytoid dendritic cells (pDC) counts
Venous blood was drawn in sodium heparin tubes and diluted in 0.9 % NaCl before applying it on Lymphoprep™ (Axis-Shield, Oslo, Norway). The buffy coat was isolated and, in cases of red blood cell contamination, lysed using dH 2 
Macrophage preparation
Buffy coat was isolated from whole blood using Lymphoprep™. Monocytes were isolated from buffy coat using magnetic activated cell sorting (MACS®) and positive selection with CD14 MicroBeads (Miltenyi Biotec); 0.5x10 6 monocytes/well were cultured in 24-well plates at 37C, 5 % CO 2 . These were differentiated for 7-9 days in AIM-V (Invitrogen, Paisley, UK) supplemented with 10 % heat-inactivated fetal calf serum (HI FCS (Invitrogen, UK) and 5 ng/ml macrophage colony-stimulating factor (M-CSF) (Peprotech, London, UK) before they were used in the phagocytosis assay.
Medium was changed twice during the differentiation period.
PMN isolation and apoptotic cells
PMNs were isolated from whole blood using Lymphoprep™ and red blood cell lysis with freshly made sterile NH 4 Cl buffer (8. 
Phagocytosis assay
Apoptotic cells (1x10 6 or 2x10 
Serum samples and IgG depletion
Serum samples were collected and pooled for use in the phagocytosis assay. All sera were handled in the same way. IgG depletion of pooled serum was done using Protein G Sepharose 4 FastFlow (GE Healthcare, Uppsala, Sweden) and Protein A Sepharose CL-4B (GE Healthcare) using the same volume Sepharose beads as volume of serum. The sera were incubated with the beads at 4C with rotation overnight and then spun down at 600 g for 1 min. Supernatant was collected and used as IgG-depleted serum. IgG depletion was confirmed in an enzyme-linked immunosorbent assay (ELISA) coated with sera before and after depletion. Detection was done with a goat anti-human IgG (Fc-specific) AP antibody (Sigma-Aldrich) and phosphatase substrate tablets (SigmaAldrich). 
Statistical analyses
Results
Plasmacytoid dendritic cells (pDCs), but not monocyte subpopulations, differ quantitatively when comparing AAV patients with HBDs
In this study we investigated if there are inherited or acquired defects in the phagocytosis of dying PMNs. First we wanted to verify that the monocytes did not differ in their pro-/anti-inflammatory differentiation or in numbers. We therefore performed differential blood cell counts on HBD (n=23), AAV (n=28) and patients with a renal transplant (TP) (n=14). Patients were in remission or had a low disease activity (see Table 1 for clinical data of patients used in this study). The total monocyte counts did not differ between the three groups (mean value for HBDs: 0.49x10 9 cells/L, AAV:
0.59x10 9 cells/L and TP: 0.65x10 9 cells/L) (Fig. 1a) . There was a significantly increased number of PMNs in AAV patients compared to HBDs (mean value: 6.0x10 9 cells/L compared to 3.8x10 9 cells/L). PMN numbers in TP patients were also increased (mean value: 4.7x10 9 cells/L), although the increases were not significant as for AAV patients.
Conversely, the numbers of lymphocytes were decreased in AAV patients compared to HBDs ( . In TP, we saw the same tendency as for AAV (mean value: 6.8x10 6 cells/L), but this was not significant (Fig. 1c) .
Macrophages from AAV and SLE patients have similar phagocytic ability as macrophages from HBDs
In order to compare phagocytic ability of MØs, cells were prepared from HBDs, AAV and SLE patients (see Table 1 ) and were allowed to engulf apoptotic cells (PMNs from
HBDs or Jurkat cells) during 1 h; the apoptotic cells were labelled fluorescently with CellTracker™ Green. Phagocytosis was measured as a percentage of CellTracker™
Green stained CD206-positive MØ using flow cytometry (Fig. 2) . These experiments were done in the presence of 10 % HI FCS to enable intrinsic differences between the different groups to be detected.
We used Jurkat cells as a control in order to compare results more effectively. Because this is a cell line, we could expect these experiments to be more stable on a day-to-day basis compared to PMNs. We thus calculated relative phagocytosis by dividing the phagocytosis value taken from one PMN experiment with the value from the corresponding Jurkat experiment performed on the same day and with the same donor.
At a MØ : apoptotic cell ratio of 1:4, we did not detect any significant differences between any of the groups (mean value of relative phagocytosis: HBD: 77% AAV: 73%, SLE: 69%) (see Fig. 3a, right panel) . At a ratio of 1:2, the mean values were, for HBD: 67%, AAV: 64%, SLE: 55%, and we could see a tendency for AAV MØ phagocytic ability to be decreased compared to HBDs, although its effect was not statistically significant (p=0.072) (see Fig. 3a, left panel) . The difference between the two MØ : apoptotic cell ratios might be explained by a saturation effect when increasing the amount of apoptotic material for the MØs. When comparing the phagocytic activity of apoptotic Jurkat cells only, there were still no significant differences between HBD MØs and AAV MØs. There was a small yet significant decrease in phagocytosis of
MØs from SLE patients compared to HBDs at a MØ : Jurkat cell ratio of 1:4 (p=0.037) (data not shown). 
PMNs from AAV and SLE patients have similar ability to become eaten by macrophages as PMNs from HBDs
We did not detect any significant differences in the ability of MØs to engulf apoptotic cells when comparing HBDs with AAV patients; we therefore turned our focus to PMNs and investigated whether apoptotic PMNs from AAV patients have a lower tendency to become engulfed compared to HBD PMNs. This would support the theory that apoptotic cells accumulate in AAV. In these experiments we used two HBD monocyte donors for all assays. The experiments were normalized to phagocytosis of apoptotic Jurkat cells, as described above. We did not detect any significant differences in either AAV or SLE patients compared to HBDs, irrespective of the MØ donor or MØ : PMN ratio (see Fig. 3b ).
As a control experiment, we stained the cells in the phagocytosis assay with a neutrophil-specific antibody directed against CD66b after ingestion, in addition to CellTracker® staining of PMNs and CD206 staining of MØs. The results show that CD66b can be detected on only a small subset of the CellTracker-stained MØ (mean of three experiments: 9,7 % 3,5 (sd)). This indicates that we mainly detect ingested apoptotic cells in our assay, but also some bound or partly ingested cells. 
Sera from AAV patients lower the phagocytic ability of macrophages
We did not detect any intrinsic differences in phagocytosis in the immune cells; we therefore investigated if serum factors affect phagocytic ability using MØ taken from four HBDs and Jurkat cells as apoptotic cells. After induction of apoptosis, we added 10 % serum from pools of eight HBDs, AAV or SLE patients in the phagocytosis assay.
In the experiments with AAV serum, we could see that phagocytosis tends to be decreased (mean value: 36 %) compared to HBD serum (mean value: 43 %), but this did not reach significance. This effect was not seen for SLE serum (mean: 45 %) (see Fig. 4a ).
Serum IgG was depleted from the serum pools and phagocytic ability was subsequently lowered, as expected, as the Fc-receptor mediated phagocytosis would be lost after depletion of IgG. Unexpectedly, the difference seen before depletion was lost and all three depleted sera stimulated phagocytosis to a similar extent (mean value for HBDs: 35 %, AAV: 33 % and SLE: 33 %) (see Fig. 4b ).
ANCA antigens are expressed on the surface of macrophages
Because we used Jurkat cells in the serum experiments, we speculate that AAV serum could affect the MØs, rather than Jurkat cells, as they do not express ANCA antigens.
We therefore measured PR3 and MPO surface expression on monocyte-derived MØ from a HBD. The results show a high expression of both antigens (91% of cells were PR3 positive, 97% were MPO positive when isotype control had been subtracted).
Whether or not the surface expression of the ANCA antigens on MØs exhibit individual variation and whether this has any impact on phagocytosis ability remains to be established. 
Discussion
The purpose of this study was to investigate whether there is a cellular defect in AAV that could explain an impaired clearance of apoptotic cells as an inducer of autoimmunity. If apoptotic cells are not cleared properly, this could lead to an accumulation of these cells that progresses eventually to secondary necrosis. This has been proposed as a pathogenic mechanism for autoimmune diseases [17, 29] . Our first approach was to determine if the cell numbers of different immune cells are normal in AAV patients compared to HBDs. In peripheral blood we detected an increased number of PMNs in AAV patients. This could be explained partly by the treatment with glucocorticoids that most of these patients were taking, because glucocorticoids are known to prolong PMN survival [30] [31]. Therefore we used patients on renal transplant therapy as a treatment control; their PMN numbers were also increased, although not as greatly as for AAV patients. This could indicate that PMNs overwhelm the phagocytic system in AAV leading to an initiation of the immune response and eventually autoimmunity. The decreased number of lymphocytes in AAV patients could also be a treatment-related effect, as these patients are treated with a varying amount of immunosuppressive drugs as well as cytotoxic drugs, all of which dampens the immune system in different ways. However, we did not detect any significant difference between AAV patients in the active state of their disease versus patients in remission, and no differences were found between different treatment regimens.
In our studies, pDCs were found to be decreased in AAV compared to both transplant patients and HBDs. pDCs are important for fighting viral infections and also have regulatory effects on other immune cells [32] . Recently, Rimbert et al. have described a decrease in pDCs in AAV patients, and this could reflect migration of these cells to tissues [33] . Interestingly, Rimbert et al. also showed an increased expression of CD62L on AAV pDCs, indicating that these pDCs could more easily be recruited to lymph nodes, where they could initiate an immune response.
We looked for clearance defects either in phagocytic ability of MØs or ability of apoptotic PMNs to be engulfed, and we did not detect any such intrinsic defect in AAV PMNs in the presence of heat-inactivated FCS. In theory, PMNs from AAV patients would lower the phagocytosis ability of MØs, as they generally express more PR3 on their surface compared to HBDs [34] , and PR3 surface exposure during apoptosis seems to be a 'don't eat me' signal [8] ; however, in that study they used PR3 transfected RBL cells and not PMNs. Thus this does not have to apply for PMNs.
There was, however, a small decrease, although not statistically significant, in the phagocytic ability of MØs in AAV patients and SLE patients (p=0.02) compared to HBDs when looking at the 1:2 MØ : PMN ratio. No differences were detected in the 1:4 ratio; this effect can possibly be explained by a saturation effect when increasing the amount of apoptotic cells. Both the AAV patients and SLE patients were generally taking glucocorticoids that could possibly skew these results, as glucocorticoids are known to augment phagocytosis [35] . In our study, however, we did not find any correlation between glucocorticoid dosage and phagocytic ability, nor did we find any correlation between phagocytosis ability and administration of rituximab, cyclophosphamide or azathioprine, although there were low numbers of patients in each treatment group (data not shown).
The age of AAV patients were significantly higher than HBDs, but no correlation was found between age of MØ donor and their phagocytosis capacity (data not shown).
Studies are inconclusive with regard to phagocytic ability and aging individuals [36] .
However, it is clear that the innate immune system is altered with age in various ways [37] .
We show that we detected mainly ingested cells in the phagocytosis assay, because the phagocyting MØs were positive for the neutrophil specific marker CD66b only to a small extent. We believe that these CD66b-positive MØs represent partly ingested PMNs, and as phagocytosis is a continuous process there will always be partly ingested cells as long as there is enough apoptotic material.
When adding serum from HBDs, AAV and SLE patients, AAV serum tended to stimulate phagocytosis less well but this did not reach significance; however, the numbers were small. These results contradict the general idea that clearance is impaired in SLE, although whether this is due to cellular defects or other factors is still under debate. [19] [38] [39] . These contradictory results could both be due to individual variations in patients and differences in experimental protocols. Our finding that AAV sera seems to lower the phagocytic ability of MØs was surprising, as it has been reported previously by Moosig et al. that apoptotic PMNs, preincubated with ANCA lead to an increased uptake by MØs compared to preincubation with control IgG [40] .
However, Moosig et al. detected phagocytosis by measuring MPO activity in MØ lysates after ingestion. Furthermore, we speculate that the ANCA might affect and bind to MØs rather than the apoptotic Jurkat cells used in our experiments, as they lack the ANCA antigens and FcRs on their surface [41] . To support this, we show that ANCA antigens are expressed readily on the surface of MØs; however, if this has any impact on phagocytosis ability remains to be established. Little is known about how ANCAs affect the monocyte/macrophage population, although it has been shown that the isolation procedure as well as tumour necrosis factor (TNF)- priming affects the level of surface expression of ANCA antigens in monocytes [42] . Furthermore, there are reports showing that incubating monocytes with ANCA-positive sera leads to an increased production of ROS [43] and proinflammatory cytokines [42] , indicating that the ANCAs can affect the monocytes to a more inflammatory phenotype. We speculate that ANCA might bind to the MØs, affecting its ability to engulf cells in our serum experiments either by binding to the ANCA antigens on the MØ surface, via Fc receptors, or both, but this requires further experiments to clarify fully.
In conclusion, this study does not confirm our hypothesis that there is a cellular phagocytic defect in MØs or apoptotic PMNs in AAV. The monocyte number, subclass distribution as well as phagocytic ability did not differ between AAV and HBDs when investigating patients in remission, nor was any difference seen in the edibility of apoptotic PMNs. However, PMN numbers were increased in circulation, which could lead possibly to an accumulation of apoptotic PMNs around the vessels and an increased antigen exposure. The fact that the number of pDCs is decreased in circulation at the same time could indicate that these have migrated to lymph nodes to initiate an immune response against the ANCA antigens PR3 and MPO. Furthermore, we found that AAV serum seems to lower the phagocytic ability of MØs, and this could be caused by ANCA. This does not explain how AAV develop in the first place, but might indicate that dysfunctional phagocytosis in AAV is a consequence of ANCA rather than the initiating factor of these. 
